JP2009524601A5 - - Google Patents

Download PDF

Info

Publication number
JP2009524601A5
JP2009524601A5 JP2008549598A JP2008549598A JP2009524601A5 JP 2009524601 A5 JP2009524601 A5 JP 2009524601A5 JP 2008549598 A JP2008549598 A JP 2008549598A JP 2008549598 A JP2008549598 A JP 2008549598A JP 2009524601 A5 JP2009524601 A5 JP 2009524601A5
Authority
JP
Japan
Prior art keywords
composition
candida
als protein
protein family
family member
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008549598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524601A (ja
JP5692963B2 (ja
Filing date
Publication date
Priority claimed from US11/327,197 external-priority patent/US20070077256A1/en
Application filed filed Critical
Publication of JP2009524601A publication Critical patent/JP2009524601A/ja
Publication of JP2009524601A5 publication Critical patent/JP2009524601A5/ja
Application granted granted Critical
Publication of JP5692963B2 publication Critical patent/JP5692963B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2008549598A 2006-01-06 2007-01-05 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法 Expired - Fee Related JP5692963B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/327,197 2006-01-06
US11/327,197 US20070077256A1 (en) 1999-11-19 2006-01-06 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
PCT/US2007/000433 WO2007081896A2 (en) 2006-01-06 2007-01-05 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012207831A Division JP5775044B2 (ja) 2006-01-06 2012-09-21 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法

Publications (3)

Publication Number Publication Date
JP2009524601A JP2009524601A (ja) 2009-07-02
JP2009524601A5 true JP2009524601A5 (https=) 2011-02-03
JP5692963B2 JP5692963B2 (ja) 2015-04-01

Family

ID=38256965

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008549598A Expired - Fee Related JP5692963B2 (ja) 2006-01-06 2007-01-05 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法
JP2012207831A Expired - Fee Related JP5775044B2 (ja) 2006-01-06 2012-09-21 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法
JP2014105980A Withdrawn JP2014148547A (ja) 2006-01-06 2014-05-22 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012207831A Expired - Fee Related JP5775044B2 (ja) 2006-01-06 2012-09-21 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法
JP2014105980A Withdrawn JP2014148547A (ja) 2006-01-06 2014-05-22 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法

Country Status (10)

Country Link
US (5) US20070077256A1 (https=)
EP (4) EP1982190B1 (https=)
JP (3) JP5692963B2 (https=)
AU (1) AU2007205065B2 (https=)
CA (2) CA2636277C (https=)
CY (1) CY1113693T1 (https=)
DK (1) DK1982190T3 (https=)
ES (3) ES2608354T3 (https=)
PT (1) PT1982190E (https=)
WO (1) WO2007081896A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) * 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
WO2011003085A1 (en) * 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
GEP201706766B (en) * 2011-07-22 2017-10-25 Los Angeles Biomedical Res Center Methods and compositions for vaccinating against staphylococcus aureus
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
JP6566616B2 (ja) * 2014-08-19 2019-08-28 キヤノン株式会社 通信装置、その制御方法、およびプログラム
US20200155449A1 (en) 2015-11-16 2020-05-21 Medincell Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
EP3426287A4 (en) * 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
US10308571B2 (en) * 2017-10-11 2019-06-04 Uop Llc Process for minimizing benzene, toluene, and a recycle loop in a zero benzene aromatics complex
JP7439371B2 (ja) * 2018-04-10 2024-02-28 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー－ ユーシーエルエー メディカル センター Ｃａｎｄｉｄａ ａｕｒｉｓ感染症の治療方法
EP3552620A1 (en) * 2018-04-11 2019-10-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods of treatment for candida auris infections
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases
WO2025248488A1 (en) * 2024-05-29 2025-12-04 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Compositions and methods for preventing and treating healthcare-associated candida auris infections with dual antigen vaccine

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346074A (en) 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
US6500438B2 (en) 1995-06-07 2002-12-31 Pfizer Incorporated In ovo vaccination against coccidiosis
DE69734601T2 (de) * 1996-05-16 2006-08-03 The Texas A & M University System, College Station Zusammensetzung von kollagenbindungsprotein und verfahren zu deren verwendungen
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
AU2003231818B2 (en) 2002-05-21 2007-04-19 Intervet International B.V. Methods for the in vitro culture of Sporozoea sp. and user thereof
US7241613B1 (en) 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
AU2003290867A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
MXPA06005639A (es) 2003-11-21 2006-08-17 Pfizer Prod Inc Adyuvante antimicrobiano.
US20050287146A1 (en) * 2003-12-19 2005-12-29 Joseph Patti Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
BRPI0711572A2 (pt) 2006-04-17 2011-11-16 Schering Plough Ltd organismos recombinantes atenuados de clostridium e vacinas
EP2164511A1 (en) 2007-05-22 2010-03-24 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
US9050281B2 (en) 2008-05-29 2015-06-09 Intervet Inc. Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
WO2011003085A1 (en) 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
GEP201706766B (en) * 2011-07-22 2017-10-25 Los Angeles Biomedical Res Center Methods and compositions for vaccinating against staphylococcus aureus
BR112014005773A2 (pt) 2011-09-14 2019-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center composições derivadas de hyr1 e métodos of tratamento usando as mesmas
WO2014144024A1 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 compositions and methods for treating fungal and bacterial pathogens
US20160030533A1 (en) 2013-03-15 2016-02-04 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods of treating fungal and bacterial pathogens
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis

Similar Documents

Publication Publication Date Title
JP2009524601A5 (https=)
Qazi et al. Corneal transparency: genesis, maintenance and dysfunction
EP3064220A3 (en) Compositions and methods for the treatment of infections and tumors
JP2010540446A5 (https=)
CY1113693T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
NZ607498A (en) Biomaterials with enhanced properties and devices made therefrom
JP2010222367A5 (https=)
BRPI0819719B8 (pt) compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
WO2010150233A3 (en) Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
WO2012077950A3 (ko) 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법
WO2008005084A3 (en) Methods to prevent and treat diseases
JP2018500390A5 (https=)
WO2011116026A3 (en) Inhibitors of beta integrin-g protein alpha subunit binding interactions
WO2007126363A3 (en) Antisecretory protein for use in the treatment of compartment syndrome
BR112013014189A8 (pt) composição farmacêutica, uso de um agente de potencialização e uso de uma composição
ECSP066916A (es) Vacuna contra estreptococo agalactiae
JP2008540453A5 (https=)
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2007018463A3 (en) Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
WO2009005798A3 (en) Antifungal formulation and method of preparation
WO2010149283A3 (de) Phenyloxy(thio)phenylamidbenzoxa(thia)zole
WO2008147468A3 (en) Compositions comprising virus-interacting layered phyllosilicates and a therapeutic agent, and methods of use
WO2006121895A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2011003665A3 (en) Method of treating hair